Literature DB >> 19583453

Outcome of antimicrobial therapy in documented biofilm-associated infections: a review of the available clinical evidence.

Matthew E Falagas1, Anastasios M Kapaskelis, Vasilios D Kouranos, Ourania K Kakisi, Zoe Athanassa, Drosos E Karageorgopoulos.   

Abstract

Numerous laboratory findings indicate that microbial biofilms may be encountered in several types of human infections, affecting the activity of antimicrobial agents. We evaluated the clinical evidence regarding the effectiveness of antimicrobial therapy for infections documented to be biofilm-associated, by performing a review of 15 relevant studies, excluding dental and eye infections. In a clinical trial, a significant difference was noted in the effectiveness of antibacterial agents used for catheter-related urinary tract infections in which substantial bacterial adherence on uroepithelial cells was observed. In case series and case reports, 28 patients with biofilm-associated infections documented by electron microscopy scanning were identified. Infection sites included ear, urinary tract, CNS, bloodstream and foreign body implantation site. Pseudomonas and Staphylococcus spp. were the predominant microorganisms among the bacterial or fungal causative pathogens. In 24 cases, infections related to the presence of foreign bodies. Treatment failure or recurrence was noted in all eight patients in whom targeted antimicrobial therapy was instituted before foreign body removal. Foreign body removal coupled with antimicrobial therapy was effective in all ten relevant cases. In four cases of native tissue urinary tract infections, the outcome of the initial antimicrobial therapy was poor. The limited available relevant clinical evidence indicates that conventional antimicrobial therapy alone is not adequately effective against documented biofilm-associated infections. Although some regimens might be more appropriate in this setting, further research on novel therapeutic strategies is needed to improve the outcome of patients with biofilm-associated infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19583453     DOI: 10.2165/00003495-200969100-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  51 in total

Review 1.  Bacterial biofilms: a common cause of persistent infections.

Authors:  J W Costerton; P S Stewart; E P Greenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

Review 2.  Quorum sensing: cell-to-cell communication in bacteria.

Authors:  Christopher M Waters; Bonnie L Bassler
Journal:  Annu Rev Cell Dev Biol       Date:  2005       Impact factor: 13.827

Review 3.  Evaluation of nonculture methods for the detection of prosthetic hip biofilms.

Authors:  Andrew McDowell; Sheila Patrick
Journal:  Clin Orthop Relat Res       Date:  2005-08       Impact factor: 4.176

4.  Direct demonstration of viable Staphylococcus aureus biofilms in an infected total joint arthroplasty. A case report.

Authors:  Paul Stoodley; Laura Nistico; Sandra Johnson; Leslie-Ann Lasko; Mark Baratz; Vikram Gahlot; Garth D Ehrlich; Sandeep Kathju
Journal:  J Bone Joint Surg Am       Date:  2008-08       Impact factor: 5.284

5.  The role of oxygen limitation in the resistance of agar-entrapped, sessile-like Escherichia coli to aminoglycoside and beta-lactam antibiotics.

Authors:  O Tresse; T Jouenne; G A Junter
Journal:  J Antimicrob Chemother       Date:  1995-09       Impact factor: 5.790

Review 6.  Periodontal diseases.

Authors:  Bruce L Pihlstrom; Bryan S Michalowicz; Newell W Johnson
Journal:  Lancet       Date:  2005-11-19       Impact factor: 79.321

7.  Biofilm formation by Propionibacterium acnes on biomaterials in vitro and in vivo: impact on diagnosis and treatment.

Authors:  Roger Bayston; Waheed Ashraf; Robert Barker-Davies; Emily Tucker; Rhys Clement; Juliet Clayton; Brian J C Freeman; Bryar Nuradeen
Journal:  J Biomed Mater Res A       Date:  2007-06-01       Impact factor: 4.396

8.  Fungal biofilm formation on cochlear implant hardware after antibiotic-induced fungal overgrowth within the middle ear.

Authors:  Ricardo Cristobal; Charles E Edmiston; Christina L Runge-Samuelson; Heather A Owen; Jill B Firszt; P Ashley Wackym
Journal:  Pediatr Infect Dis J       Date:  2004-08       Impact factor: 2.129

9.  Coagulase-negative staphylococcus in chronic prostatitis.

Authors:  J C Nickel; J W Costerton
Journal:  J Urol       Date:  1992-02       Impact factor: 7.450

Review 10.  Prostatitis.

Authors:  G J Domingue; W J Hellstrom
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

View more
  15 in total

1.  Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.

Authors:  Stefan Hajdu; Johannes Holinka; Sonja Reichmann; Alexander M Hirschl; Wolfgang Graninger; Elisabeth Presterl
Journal:  Antimicrob Agents Chemother       Date:  2010-08-02       Impact factor: 5.191

2.  Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.

Authors:  Shengzheng Wang; Yan Wang; Wei Liu; Na Liu; Yongqiang Zhang; Guoqiang Dong; Yang Liu; Zhengang Li; Xiaomeng He; Zhenyuan Miao; Jianzhong Yao; Jian Li; Wannian Zhang; Chunquan Sheng
Journal:  ACS Med Chem Lett       Date:  2014-02-13       Impact factor: 4.345

3.  Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.

Authors:  Katie E Barber; Jordan R Smith; Cortney E Ireland; Blaise R Boles; Warren E Rose; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

4.  Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.

Authors:  Jorge Parra-Ruiz; Celine Vidaillac; Warren E Rose; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

5.  Small lipopeptides possess anti-biofilm capability comparable to daptomycin and vancomycin.

Authors:  Biswajit Mishra; Tamara Lushnikova; Guangshun Wang
Journal:  RSC Adv       Date:  2015       Impact factor: 3.361

6.  Comparison of scanning electron microscopy findings regarding biofilm colonization with microbiological results in nasolacrimal stents for external, endoscopic and transcanalicular dacryocystorhinostomy.

Authors:  Melike Balikoglu-Yilmaz; Tolga Yilmaz; Sule Cetinel; Umit Taskin; Ayse Banu Esen; Muhittin Taskapili; Timur Kose
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

7.  High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors.

Authors:  Samuel A Siles; Anand Srinivasan; Christopher G Pierce; José L Lopez-Ribot; Anand K Ramasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

8.  Identification of novel cyclic lipopeptides from a positional scanning combinatorial library with enhanced antibacterial and antibiofilm activities.

Authors:  Nina Bionda; Renee M Fleeman; César de la Fuente-Núñez; Maria C Rodriguez; Fany Reffuveille; Lindsey N Shaw; Irena Pastar; Stephen C Davis; Robert E W Hancock; Predrag Cudic
Journal:  Eur J Med Chem       Date:  2015-11-30       Impact factor: 6.514

9.  A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms.

Authors:  Julia Bauer; Wafi Siala; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

10.  Clinical outcomes of antimicrobial lock solutions used in a treatment modality: a retrospective case series analysis.

Authors:  P Brandon Bookstaver; Katherine R Gerrald; Robert R Moran
Journal:  Clin Pharmacol       Date:  2010-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.